🔴 NeoGenomics is trading 6.1% down today with no company-specific catalyst identified

NeoGenomics is trading 6.06% lower at $16.90 on October 29; no specific company-related catalyst for the decline was identified.

• The strong October 28 third-quarter report included $209 million in revenue, 29% NGS revenue growth, and higher adjusted EBITDA.
• Management raised 2026 guidance to $807–$809 million in revenue and about $60 million in adjusted EBITDA.
• The Nasdaq is down 1.37%, while healthcare is up 2.32%; risk-off sentiment may contribute, but the earnings beat does not explain the drop.